ERBB2 and breast cancer: MPO levels were significantly elevated in HER2+ breast cancer patients by 3 months of treatment and were significantly associated with cardiotoxicity during the entire treatment course of doxorubicin/trastuzumab with HR = 1.37 (95% CI (1.11–1.69); p = 0.02) [98].